Immunotherapy for pediatric leukemia

Front Oncol. 2013 Jul 1;3:166. doi: 10.3389/fonc.2013.00166. eCollection 2013.


Substantial progress has been made in the treatment of leukemia in childhood. Despite this, leukemia remains a leading cause of pediatric cancer-related mortality and the prognosis is guarded for individuals with relapsed or refractory disease. Standard therapies are associated with a wide array of acute and long-term toxicities and further treatment intensification may not be tolerable or beneficial. The curative potential of allogeneic stem cell transplantation is due in part to the graft-versus-leukemia effect, which provides evidence for the therapeutic capacity of immune-based therapies. In recent years there have been significant advances in the development and application of immunotherapy in the treatment of leukemias, including the demonstration of activity in chemotherapy-resistant cases. This review summarizes immunotherapeutic approaches in the treatment of pediatric leukemia including current results and future directions.

Keywords: acute lymphoblastic leukemia; adoptive cell therapy; application of immunotherapy; hematologic malignancies; immunotherapy; monoclonal antibodies; pediatric leukemia.